POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride is a potassium supplement that replaces potassium ions lost from the body. Dextrose 5% provides a source of calories and may enhance potassium uptake into cells via insulin-mediated mechanisms. Sodium chloride 0.45% provides sodium and chloride to maintain electrolyte balance.
| Metabolism | Potassium is not metabolized; it is primarily excreted by the kidneys. Dextrose is metabolized via glycolysis and oxidative phosphorylation. Sodium and chloride are not metabolized. |
| Excretion | Primarily renal (90% excreted in urine as potassium ions), with minimal fecal (<5%) and negligible biliary elimination. |
| Half-life | Not applicable as potassium is an electrolyte; serum half-life varies with distribution; redistribution half-life approximately 1-1.5 hours. |
| Protein binding | Not significantly bound (<5%); does not bind to plasma proteins. |
| Volume of Distribution | 0.5-0.7 L/kg; approximates total body water (0.6 L/kg) with slight variation based on age and body composition. |
| Bioavailability | Oral: 90-100% (well absorbed from gastrointestinal tract). Intravenous: 100%. |
| Onset of Action | Intravenous: within minutes (correction of hypokalemia). Oral: 30-60 minutes (gastrointestinal absorption). |
| Duration of Action | Intravenous: 1-2 hours (rapid redistribution). Oral: 4-6 hours (sustained release formulations up to 8-10 hours). |
| Molecular Weight | 74.55 |
Intravenous infusion; 10 mEq potassium chloride in 1000 mL of solution (D5W + 0.45% NaCl) at a rate not exceeding 10 mEq/hour and total daily dose not exceeding 200 mEq, with continuous ECG monitoring. Typical adult dose: 10-20 mEq infused over 1-2 hours, repeated as needed based on serum potassium levels.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: Use with extreme caution; initial dose reduction by 50% and titrate based on serum potassium. GFR 30-59 mL/min: Reduce dose by 25-50% or extend dosing interval. GFR ≥60 mL/min: No adjustment required. |
| Liver impairment | No specific adjustment recommended for Child-Pugh class A or B; however, monitor serum potassium closely. For Child-Pugh class C, consider dose reduction of 25-50% due to possible impaired potassium handling. |
| Pediatric use | Dose: 0.5-1 mEq/kg/dose intravenously, maximum 10 mEq/dose, infused at a rate not exceeding 0.5 mEq/kg/hour. May repeat based on serum potassium. Typically administered in similar diluent concentration as adults. |
| Geriatric use | Start at low end of dosing range due to decreased renal function and increased risk of hyperkalemia. Maximum infusion rate: 5 mEq/hour. Monitor renal function and serum potassium frequently. |
| 1st trimester | Potassium chloride is generally considered safe in all trimesters when used as a supplement for hypokalemia or as part of maintenance fluids. No increased risk of major birth defects has been reported with standard doses. However, high systemic levels may theoretically affect fetal heart rhythm. |
| 2nd trimester | Same as T1. Use with caution in conditions predisposing to hyperkalemia. |
| 3rd trimester | Use with caution in preeclampsia or renal impairment due to risk of maternal hyperkalemia, which can cause fetal bradycardia. Monitor serum potassium levels. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium readily crosses the placenta via active transport. Fetal serum potassium levels are maintained within a narrow range. Maternal hyperkalemia can lead to fetal hyperkalemia and cardiac effects. |
| Breastfeeding | Potassium chloride is a normal constituent of breast milk. Supplementation does not significantly alter milk potassium levels. Use with caution in mothers with renal impairment or conditions affecting potassium homeostasis. |
| Lactation Rating | L1 |
| Teratogenic Risk | Potassium chloride, dextrose, and sodium chloride are not teratogenic. No fetal risks are expected from standard electrolyte and fluid replacement. However, hyperkalemia, hyperglycemia, or hypernatremia due to excessive administration may cause fetal arrhythmias, metabolic acidosis, or fluid overload. First trimester: No evidence of malformations. Second/third trimester: Risk from maternal electrolyte disturbances. |
| Fetal Monitoring | Monitor serum potassium, glucose, sodium, and chloride levels regularly. Assess renal function, fluid balance, and signs of hyperkalemia (ECG changes, muscle weakness) or hyperglycemia. Fetal monitoring: heart rate tracing in cases of maternal electrolyte abnormalities or fluid overload, especially in preeclampsia or gestational diabetes. |
| Fertility Effects | No known effects on fertility. Potassium, dextrose, and sodium chloride are essential nutrients and do not impair reproductive function when used at therapeutic doses. |
■ FDA Black Box Warning
Concentrated potassium chloride solutions must be diluted before use; rapid infusion can cause fatal hyperkalemia and cardiac arrest. Do not administer undiluted.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's diseaseAcute dehydrationHeat crampsConcurrent use of potassium-sparing diuretics (e.g., spironolactone, amiloride)
| Precautions | Monitor serum potassium levels, renal function, and ECG during administration, Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Risk of hyperkalemia, especially with rapid infusion or in patients with impaired potassium excretion, Contains dextrose; may cause hyperglycemia in patients with diabetes mellitus, Sodium content should be considered in patients with hypertension, heart failure, or edema |
| Food/Dietary | Avoid potassium-rich foods (e.g., bananas, oranges, potatoes, tomatoes, spinach) unless directed by your doctor, especially if you have kidney issues or are on other potassium-containing medications. |
| Clinical Pearls | Monitor serum potassium levels closely; infusion rate should not exceed 10 mEq/hour via peripheral line to avoid phlebitis. Use central line for concentrations >10 mEq/100 mL. Avoid in patients with severe renal impairment or hyperkalemia. Check for compatibility with other IV medications. |
| Patient Advice | Report any pain, redness, or swelling at the injection site immediately. · Do not stop the infusion without consulting your healthcare provider. · Inform your doctor if you have kidney problems or are on potassium-sparing diuretics. · This medication is given to correct or prevent low potassium levels. |
Loading safety data…